Neuralstem (CUR) Stock Rises Today as Brainstorm Cell Therapeutics Soars

The company describes NurOwn as an "autologous, adult stem cell therapy technology" designed to treat ALS, also known as Lou Gehrig's Disease. "We are very excited to share the final results of this study," said Brainstorm's CEO Tony Fiorino, MD, PhD, in a company statement.

http://ift.tt/1wKakbV